Johnson & Johnson (JNJ), AbbVie Inc (ABBV), GlaxoSmithKline plc (ADR) (GSK): The Impact of a Failed Crohn’s Disease Trial Study

Similarly, Humira has a strong clinical profile. It is a well accepted drug with potential benefits in the treatment of Crohn’s disease along with other inflammatory diseases. In the recent quarter ended June 30, 2013, Humira’s sales were $2.6 billion, an increase by 12.8% at constant currency compared to prior year. The product will continue to report higher sales in the coming quarters with recent approvals for related gastrointestinal disorders. AbbVie Inc (NYSE:ABBV) expects incremental sales of more than $1.5 billion from this new indication.

Conclusion

Trial results stalled vercirnon’s hopes against its competitors in Crohn’s disease therapies. Further studies on its efficacy and safety will improve its position going forward. In addition, this is a novel molecule that is not yet approved or licensed for use anywhere in the world. Over the years, if the company develops it for other indications, there may be some upside to its potential. For the time being, however, investors will have to wait and see whether GlaxoSmithKline plc (ADR) (NYSE:GSK) and its partner will move forward with the development of this drug.

The article The Impact of a Failed Crohn’s Disease Trial Study originally appeared on Fool.com and is written by Kanak Kanti De.

Kanak Kanti De has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.